Jupiter Endovascular, Inc., based in Menlo Park, California, has announced promising outcomes from its SPIRARE I first-in-human study. The results, presented on October 26, 2025, at the Transcatheter Cardiovascular Therapeutics (TCT 2025) conference, highlight the effectiveness of the company’s innovative Transforming Fixation (TFX) technology in endovascular interventions.
The study was led by Professor Irene Lang, MD, who is the Principal Investigator and a Professor of Vascular Biology at the Medical University of Vienna in Austria. The findings suggest that TFX technology could represent a significant advancement in endovascular treatment options.
The SPIRARE I study was conducted to evaluate the safety and efficacy of the TFX technology in a first-in-human setting. Results indicated a favorable safety profile, with minimal complications reported during the trial. Furthermore, the technology demonstrated promising efficacy in achieving successful vascular interventions.
Jupiter Endovascular’s TFX technology aims to address critical needs in the field of vascular surgery. By improving fixation methods, the technology could potentially enhance patient outcomes and reduce recovery times. The positive results from the SPIRARE I study have generated significant interest from the medical community, particularly in the field of vascular therapies.
During the presentation at TCT 2025, Professor Lang emphasized the importance of these findings. She stated, “The SPIRARE I study shows great potential for TFX technology in transforming the landscape of endovascular treatments. Our results encourage further investigation and development.”
As the medical field continues to evolve, the implications of these results could be far-reaching. Jupiter Endovascular plans to conduct additional studies to further validate the efficacy of the TFX technology and expand its applications within the field.
The company’s commitment to innovation in medical technology is evident in its ongoing research and development efforts. With a focus on enhancing patient care through advanced endovascular solutions, Jupiter Endovascular is poised to make a significant impact in the healthcare sector.
The full details of the SPIRARE I study and its implications for the future of endovascular interventions will likely be a focal point in upcoming discussions at medical conferences and in publications, as more professionals recognize the potential of TFX technology.
With the successful presentation of these results, Jupiter Endovascular continues to position itself as a leader in the development of cutting-edge medical technologies that could reshape treatment paradigms in vascular care.
